NCT06655701

Brief Summary

The primary aim of our study is to evaluate the presence of stress urinary incontinence in postmenopausal patients with and without osteoporosis, determine its impact on quality of life, and explore its relationship with sarcopenia.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 22, 2024

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 23, 2024

Completed
23 days until next milestone

Study Start

First participant enrolled

November 15, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2025

Completed
Last Updated

December 12, 2024

Status Verified

December 1, 2024

Enrollment Period

2 months

First QC Date

October 22, 2024

Last Update Submit

December 9, 2024

Conditions

Outcome Measures

Primary Outcomes (4)

  • Presence of Stress Urinary Incontinence:

    Stress urinary incontinence (SUI) is the involuntary leakage of urine during physical activities that increase abdominal pressure, such as coughing, sneezing, or lifting. In this study, the presence of SUI will be determined through a questionnaire that asks participants about symptoms and frequency of urine leakage during such activities.

    0 day

  • Incontinence Quality of Life Scale (I-QOL):

    The I-QOL is a validated questionnaire that measures the impact of urinary incontinence on a patient's quality of life. It assesses how incontinence affects daily activities, social interactions, and emotional well-being. Higher scores indicate better quality of life, while lower scores suggest that incontinence has a more significant negative impact on the patient's day-to-day functioning.

    0 day

  • Skeletal Muscle Mass:

    Measured by bioelectrical impedance analysis (BIA), this assesses the amount of muscle tissue in the body. Low skeletal muscle mass indicates sarcopenia.

    0 day

  • Handgrip Strength

    This is a simple test to measure muscle strength. Reduced handgrip strength is a sign of sarcopenia.

    0 day

Study Arms (2)

Postmenopausal osteoporosis

Postmenopausal osteoporosis is diagnosed using Dual-X-ray Absorptiometry (DXA), which measures bone mineral density (BMD) and provides a T-score. A T-score of -2.5 or lower confirms the diagnosis of osteoporosis.

Diagnostic Test: No intervention

Postmenopausal non-osteoporotic women

These women maintain normal bone mineral density (BMD) levels, typically assessed using Dual-X-ray Absorptiometry (DXA). A T-score above -1.0 is considered normal.

Diagnostic Test: No intervention

Interventions

No interventionDIAGNOSTIC_TEST

No intervention

Postmenopausal non-osteoporotic womenPostmenopausal osteoporosis

Eligibility Criteria

Age50 Years - 75 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Postmenopausal women

You may qualify if:

  • Postmenopausal women with DXA measurements performed within the last 6 months.
  • Based on DXA measurements:
  • Femoral neck and L1-L4 T-scores of -1 and above will be included in the control group (non-osteoporotic).
  • Femoral neck and L1-L4 T-scores of -2.5 and below will be included in the osteoporosis group.
  • Aged 50-75 years

You may not qualify if:

  • Refusal to participate in the study.
  • History of neurological diseases, infections, surgeries, or trauma that could cause urinary incontinence or muscle loss.
  • Presence of psychiatric disorders.
  • Cognitive impairments.
  • Use of medications that could affect the study results.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beylikdüzü State Hospital

Istanbul, 34147, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Osteoporosis, Postmenopausal

Condition Hierarchy (Ancestors)

OsteoporosisBone Diseases, MetabolicBone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic Diseases

Central Study Contacts

Büşra Şirin Ahısha, MD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Target Duration
1 Day
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle Investigator

Study Record Dates

First Submitted

October 22, 2024

First Posted

October 23, 2024

Study Start

November 15, 2024

Primary Completion

January 15, 2025

Study Completion

January 15, 2025

Last Updated

December 12, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations